A Phase 2a Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter, Proof-of-concept Clinical Study to Evaluate the Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2a Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter, Proof-of-concept Clinical Study to Evaluate the Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to evaluate the clinical efficacy and safety of combination therapy with guselkumab and golimumab in participants with moderately to severely active ulcerative colitis (UC).
Inclusion Criteria:
Exclusion Criteria:
Caba, C1128AAF, Argentina
Caba, C1426ABP, Argentina
Ciudad de Buenos Aires, C1430EGF, Argentina
North Terrace, 5000, Australia
NSW, 2109, Australia
Goiânia, 74535-170, Brazil
Kharkiv, 61037, Ukraine
Kharkiv, 61039, Ukraine
Lviv, 79007, Ukraine
Lviv, 79010, Ukraine
Odesa, 65025, Ukraine
Ternopil, 46002, Ukraine